Impact of Time to Treatment Initiation on Quality of Response in Patients with Acute Myeloid Leukemia Receiving Intensive Chemotherapy.

IF 4.5 2区医学 Q1 ONCOLOGY

Cancers Pub Date : 2025-06-18 DOI:10.3390/cancers17122028

Elisa Buzzatti, Giovangiacinto Paterno, Raffaele Palmieri, Fabiana Esposito, Lucia Cardillo, Kristian Taka, Lucrezia De Marchi, Marco Zomparelli, Kleda Zaganjori, Flavia Mallegni, Elisa Meddi, Federico Moretti, Ilaria Cerroni, Carmelo Gurnari, Luca Maurillo, Francesco Buccisano, Adriano Venditti, Maria Ilaria Del Principe

{"title":"Impact of Time to Treatment Initiation on Quality of Response in Patients with Acute Myeloid Leukemia Receiving Intensive Chemotherapy.","authors":"Elisa Buzzatti, Giovangiacinto Paterno, Raffaele Palmieri, Fabiana Esposito, Lucia Cardillo, Kristian Taka, Lucrezia De Marchi, Marco Zomparelli, Kleda Zaganjori, Flavia Mallegni, Elisa Meddi, Federico Moretti, Ilaria Cerroni, Carmelo Gurnari, Luca Maurillo, Francesco Buccisano, Adriano Venditti, Maria Ilaria Del Principe","doi":"10.3390/cancers17122028","DOIUrl":null,"url":null,"abstract":"Background: Acute myeloid leukemia (AML) necessitates timely treatment, yet the impact of prolonged time to treatment (TTT) on clinical outcomes remains debated, especially its impact on achieving measurable residual disease (MRD) negativity, a powerful prognostic indicator in AML.Methods: This retrospective study analyzed 196 adult AML patients treated with intensive chemotherapy, evaluating the effect of TTT on outcome measures and quality of response. TTT was categorized arbitrarily into <8, 8-14, and >14 days.Results: Results showed a median TTT of 11 days. Median overall survival (OS) was 414 days, with no significant differences among TTT groups (p = 0.48). Complete remission rate was 75.5%, with significantly higher rates in patients treated within 14 days (p = 0.004 and p = 0.006 for 8-14 and <8 days, respectively) compared to >14 days. MRD was assessed in 140 patients, with 35% achieving negativity, and no significant differences observed among TTT groups.Conclusions: This study suggests that a treatment delay of up to 14 days does not negatively impact OS or MRD negativity. This timeframe potentially allows for thorough patient evaluation, including detailed genetic profiling and comorbidity assessment, facilitating a more personalized and optimized therapeutic strategy.","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 12","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191022/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers17122028","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Acute myeloid leukemia (AML) necessitates timely treatment, yet the impact of prolonged time to treatment (TTT) on clinical outcomes remains debated, especially its impact on achieving measurable residual disease (MRD) negativity, a powerful prognostic indicator in AML.

Methods: This retrospective study analyzed 196 adult AML patients treated with intensive chemotherapy, evaluating the effect of TTT on outcome measures and quality of response. TTT was categorized arbitrarily into <8, 8-14, and >14 days.

Results: Results showed a median TTT of 11 days. Median overall survival (OS) was 414 days, with no significant differences among TTT groups (p = 0.48). Complete remission rate was 75.5%, with significantly higher rates in patients treated within 14 days (p = 0.004 and p = 0.006 for 8-14 and <8 days, respectively) compared to >14 days. MRD was assessed in 140 patients, with 35% achieving negativity, and no significant differences observed among TTT groups.

Conclusions: This study suggests that a treatment delay of up to 14 days does not negatively impact OS or MRD negativity. This timeframe potentially allows for thorough patient evaluation, including detailed genetic profiling and comorbidity assessment, facilitating a more personalized and optimized therapeutic strategy.

查看原文本刊更多论文

开始治疗时间对急性髓系白血病患者强化化疗反应质量的影响。

背景：急性髓性白血病（AML）需要及时治疗，但延长治疗时间（TTT）对临床结果的影响仍存在争议，特别是其对实现可测量残余疾病（MRD）阴性的影响，这是AML的一个强有力的预后指标。方法：本回顾性研究分析了196例接受强化化疗的成年AML患者，评估TTT对结局指标和反应质量的影响。TTT被随意分为14天。结果：结果显示中位TTT为11天。中位总生存期（OS）为414天，TTT组间差异无统计学意义（p = 0.48）。完全缓解率为75.5%，14天内治疗的患者完全缓解率显著高于8-14天和14天（p = 0.004和p = 0.006）。140例患者进行MRD评估，35%为阴性，TTT组间无显著差异。结论：这项研究表明，治疗延迟长达14天不会对OS或MRD的消极性产生负面影响。这个时间框架可能允许彻底的患者评估，包括详细的基因分析和合并症评估，促进更个性化和优化的治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancers Medicine-Oncology

CiteScore

8.00

自引率

9.60%

发文量

5371

审稿时长

18.07 days

期刊介绍： Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.